Markets:

Overview

News

Currencies

International

Treasuries

Genmab A/S - American Depositary Shares (NQ:GMAB)

29.29 +0.27 (+0.91%)

Streaming Delayed Price Updated: 3:02 PM EDT, Aug 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Genmab A/S - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 22, 2025

From Genmab A/S

Via Business Wire

GENMAB A/S -SP ADR (NASDAQ:GMAB) - A Strong Candidate for Affordable Growth Investors ↗

May 21, 2025

GENMAB A/S (NASDAQ:GMAB) offers strong growth, solid profitability, and attractive valuation, making it a compelling choice for investors seeking affordable growth stocks in the biotech sector.

Via Chartmill

GENMAB A/S -SP ADR (NASDAQ:GMAB) - A Strong Candidate for GARP Investors ↗

May 15, 2025

GENMAB A/S (NASDAQ:GMAB) offers strong growth, profitability, and a reasonable valuation, making it a standout pick for GARP investors following Peter Lynch’s strategy.

Via Chartmill

Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress

May 14, 2025

From Genmab A/S

Via Business Wire

Breaking Down Genmab: 4 Analysts Share Their Views ↗

March 11, 2025

Via Benzinga

NASDAQ:GMAB: a strong growth stock preparing for the next leg up?. ↗

January 03, 2025

Exploring the Growth Potential of GENMAB A/S -SP ADR (NASDAQ:GMAB) as It Nears a Breakout.

Via Chartmill

GENMAB A/S -SP ADR (NASDAQ:GMAB) appears to be flying under the radar despite its strong fundamentals. ↗

May 06, 2025

GENMAB A/S -SP ADR is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:GMAB showcases decent financial health and profitability, coupled with an attractive price.

Via Chartmill

Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

May 01, 2025

From Genmab A/S

Via Business Wire

GENMAB A/S -SP ADR (NASDAQ:GMAB): A Strong Affordable Growth Stock ↗

May 01, 2025

GENMAB A/S -SP ADR (NASDAQ:GMAB): A Strong Affordable Growth Stock

Via Chartmill

GENMAB A/S -SP ADR (NASDAQ:GMAB): a strong growth stock preparing for the next leg up?. ↗

April 29, 2025

Based on a technical and fundamental analysis of NASDAQ:GMAB we can say: GENMAB A/S -SP ADR (NASDAQ:GMAB), a strong growth stock, setting up for a breakout.

Via Chartmill

While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable. ↗

December 31, 2024

NASDAQ:GMAB is not too expensive for the growth it is showing.

Via Chartmill

Why Peter Lynch may take an interest in GENMAB A/S -SP ADR (NASDAQ:GMAB) ↗

April 23, 2025

Peter Lynch, one of the most successful investors of all time, focused on growth stocks with strong fundamentals and a business model that’s easy to understand. Let’s analyze whether GENMAB A/S -SP ADR...

Via Chartmill

Despite its growth, GENMAB A/S -SP ADR (NASDAQ:GMAB) remains within the realm of affordability. ↗

April 19, 2025

GENMAB A/S -SP ADR was identified as a growth stock that isn't overvalued. NASDAQ:GMAB is excelling in various growth indicators while maintaining a solid financial footing.

Via Chartmill

Genmab Stock Rises On Strong Darzalex Sales In Q1: Retail Remains Extremely Bullish ↗

April 15, 2025

Genmab receives royalties on the worldwide net sales of Darzalex, both the intravenous and subcutaneous products, under J&J's exclusive worldwide license to develop, manufacture, and commercialize...

Via Stocktwits

Topics Stocks

What Analysts Are Saying About Genmab Stock ↗

April 09, 2025

Via Benzinga

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

March 31, 2025

From Genmab A/S

Via Business Wire

Does GENMAB A/S -SP ADR (NASDAQ:GMAB) match Peter Lynch’s “Invest in What You Know” philosophy? ↗

March 28, 2025

Peter Lynch was known for finding hidden gems in the market before they became mainstream. Is GENMAB A/S -SP ADR (NASDAQ:GMAB) one of those under-the-radar stocks that fits his legendary strategy?

Via Chartmill

Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer ↗

March 27, 2025

Genmab's Tivdak wins Japan's approval for advanced cervical cancer after a Phase 3 trial showed improved survival over chemotherapy.

Via Benzinga

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy

March 27, 2025

From Genmab A/S

Via Business Wire

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

March 17, 2025

From Genmab

Via Business Wire

Coinbase, Apple And Robinhood Are Among Top Large-Cap Losers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio? ↗

March 16, 2025

Large-cap stocks worst performers last week: TER, TTD, COIN, SAIL, GMAB, IBKR, DAL, ADBE, EXPE, HOOD, UAL, AAPL. Are they in your portfolio?

Via Benzinga

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

March 10, 2025

From Genmab A/S

Via Business Wire

Don't overlook GENMAB A/S -SP ADR (NASDAQ:GMAB)—a stock with solid growth prospects and a reasonable valuation. ↗

March 10, 2025

GENMAB A/S -SP ADR was identified as an affordable growth stock. NASDAQ:GMAB is showing great growth, but also scores well on profitability. At the same time it seems to be priced reasonably.

Via Chartmill

Why GENMAB A/S -SP ADR (NASDAQ:GMAB) Is a Promising High-Growth Stock in the Midst of Consolidation. ↗

March 04, 2025

Based on technical and fundamental analysis of NASDAQ:GMAB we find: GENMAB A/S -SP ADR (NASDAQ:GMAB) qualifies as a high growth stock and is consolidating.

Via Chartmill

EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma

February 20, 2025

From Genmab A/S

Via Business Wire

In a market where value is scarce, NASDAQ:GMAB offers a refreshing opportunity with its solid fundamentals. ↗

February 19, 2025

Take a closer look at GENMAB A/S -SP ADR , a remarkable value stock. NASDAQ:GMAB excels in fundamentals and maintains a very reasonable valuation.

Via Chartmill

Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced. ↗

February 17, 2025

Uncover the potential of GENMAB A/S -SP ADR, a growth stock reasonably priced. NASDAQ:GMAB is excelling in growth aspects, maintaining a healthy financial position, and still offers an attractive...

Via Chartmill

NASDAQ:GMAB: a strong growth stock preparing for the next leg up?. ↗

January 28, 2025

Based on technical and fundamental analysis of NASDAQ:GMAB we find: GENMAB A/S -SP ADR (NASDAQ:GMAB) qualifies as a high growth stock and is consolidating.

Via Chartmill

Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation. ↗

January 21, 2025

Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation.

Via Chartmill

When you look at NASDAQ:GMAB, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. ↗

January 10, 2025

For those who appreciate value investing, GENMAB A/S -SP ADR (NASDAQ:GMAB) is a compelling option with its solid fundamentals.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Genmab A/S - American Depositary Shares (NQ:GMAB)

All News about Genmab A/S - American Depositary Shares

Starting at /week.